Key result
CRP apheresis is linked to ~5% smaller infarct size and improved LVEF in high-CRP STEMI patients.
Why the study?
The sustainability of the effect of CRP apheresis on cardiac damage after STEMI beyond the initial treatment period was unknown.
Does CRP apheresis improve myocardial infarct size and left ventricular function in patients with STEMI?
Does CRP apheresis improve myocardial infarct size and left ventricular function in patients with STEMI?
Mean Difference: -5.4
p-value: p=0.05
CRP apheresis after STEMI may provide sustained improvements in infarct size and left ventricular function, particularly in patients with high initial CRP production.
No takes yet. Share an insight, caveat, or question.
CRP apheresis achieves post-STEMI CRP reduction; leaves open effects on infarct size or LVEF pending randomized trials.
Skarabis et al. (2022) studied ST-Elevation Myocardial Infarction (STEMI) (n=66). C-reactive protein (CRP) apheresis vs. Control group was evaluated on Myocardial infarct size (IS) (MD -5.4%, p=0.05). In STEMI patients with high CRP production (>0.6 mg/L/h), CRP apheresis significantly reduced myocardial infarct size (-5.4%; p=0.05) and improved LVEF (+6.4%; p=0.03) at 88 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: